

## Income statement

x € million	2015	2014 <sup>1</sup>
Net sales, continuing operations	7,722	7,051
<b>Operating profit before depreciation and amortization (EBITDA)<sup>2</sup></b>	<b>1,075</b>	<b>1,038</b>
<b>Operating profit before exceptional items<sup>2</sup></b>	<b>573</b>	<b>587</b>
Net finance costs	(149)	(102)
Income tax expense	(97)	(84)
Share of the profit of associates	54	8
Profit attributable to non-controlling interests	2	5
<b>Net profit continuing operations before exceptional items</b>	<b>383</b>	<b>414</b>
Net profit from discontinued operations before exceptional items	33	12
Net result from exceptional items, continuing operations	(199)	(122)
Net result from exceptional items, discontinued operations	(129)	(159)
<b>Total net profit attributable to equity holders of Koninklijke DSM N.V.</b>	<b>88</b>	<b>145</b>
ROCE, continuing operations (in %)	7.6	8.2
EBITDA / net sales, continuing operations (in %)	13.9	14.7

<sup>1</sup> Restated due to the disposal of the caprolactam, acrylonitrile and composite resins business

<sup>2</sup> From continuing operations